HIV-Gag VLPs presenting trimeric HIV-1 gp140 spikes constitutively expressed in stable double transfected insect cell line

Vaccine

Volumn 29, Issue 31, 2011, Pages 4913-4922

  Tagliamonte, M ^a   Visciano, M L ^a   Tornesello, M L ^a   De Stradis, A ^b   Buonaguro, F M ^a   Buonaguro, L ^a,c  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b CNR   (Italy)

^c UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Delivery system; HIV; Insect cells; Stable expression; Virus Like Particles

Indexed keywords

GAG PROTEIN; GLYCOPROTEIN GP 140;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; GENETIC TRANSFECTION; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOGENICITY; IN VIVO STUDY; INSECT CELL; MOUSE; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN EXPRESSION; TRANSMISSION ELECTRON MICROSCOPY; VIRUS ENVELOPE; VIRUS LIKE AGENT; VIRUS SPIKE; WESTERN BLOTTING;

ANIMALS; BLOTTING, WESTERN; CELL LINE; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; GENE EXPRESSION; INSECTS; MICROSCOPY, ELECTRON, TRANSMISSION; TRANSFECTION; VIROSOMES;

EID: 79959768622     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.05.004     Document Type: Article

References (65)

1. Buonaguro L., Tornesello M.L., Buonaguro F.M. Virus-Like Particles as particulate vaccines. Curr HIV Res 2010, 8:299-309.
2. Noad R., Roy P. Virus-like particles as immunogens. Trends Microbiol 2003, 11:438-444.
3. Young K.R., McBurney S.P., Karkhanis L.U., Ross T.M. Virus-like particles: designing an effective AIDS vaccine. Methods 2006, 40(September (1)):98-117.
4. Buonaguro F.M., Tornesello M.L., Buonaguro L. Virus-like particle vaccines and adjuvants: the HPV paradigm. Expert Rev Vaccines 2009, 8(October (10)):1379-1398.
5. Takamura S., Niikura M., Li T.C., Takeda N., Kusagawa S., Takebe Y., et al. DNA vaccine-encapsulated virus-like particles derived from an orally transmissible virus stimulate mucosal and systemic immune responses by oral administration. Gene Ther 2004, 11(April (7)):628-635.
6. Malboeuf C.M., Simon D.A., Lee Y.E., Lankes H.A., Dewhurst S., Frelinger J.G., et al. Human papillomavirus-like particles mediate functional delivery of plasmid DNA to antigen presenting cells in vivo. Vaccine 2007, 25(April (17)):3270-3276.
7. Touze A., Coursaget P. In vitro gene transfer using human papillomavirus-like particles. Nucleic Acids Res 1998, 26(March (5)):1317-1323.
8. Ruedl C., Schwarz K., Jegerlehner A., Storni T., Manolova V., Bachmann M.F. Virus-like particles as carriers for T-cell epitopes: limited inhibition of T-cell priming by carrier-specific antibodies. J Virol 2005, 79(January (2)):717-724.
9. Moron V.G., Rueda P., Sedlik C., Leclerc C. In vivo, dendritic cells can cross-present virus-like particles using an endosome-to-cytosol pathway. J Immunol 2003, 171:2242-2250.
10. Ruedl C., Storni T., Lechner F., Bachi T., Bachmann M.F. Cross-presentation of virus-like particles by skin-derived CD8(-) dendritic cells: a dispensable role for TAP. Eur J Immunol 2002, 32(March (3)):818-825.
11. Bachmann M.F., Lutz M.B., Layton G.T., Harris S.J., Fehr T., Rescigno M., et al. Dendritic cells process exogenous viral proteins and virus-like particles for class I presentation to CD8+ cytotoxic T lymphocytes. Eur J Immunol 1996, 26(November (11)):2595-2600.
12. Woo W.P., Doan T., Herd K.A., Netter H.J., Tindle R.W. Hepatitis B surface antigen vector delivers protective cytotoxic T-lymphocyte responses to disease-relevant foreign epitopes. J Virol 2006, 80(April (8)):3975-3984.
13. Griffiths J.C., Harris S.J., Layton G.T., Berrie E.L., French T.J., Burns N.R., et al. Hybrid human immunodeficiency virus Gag particles as an antigen carrier system: Induction of cytotoxic T-cell and humoral responses by a Gag:V3 fusion. J Virol 1993, 67:3191-3198.
14. Wagner R., Deml L., Flie-bach H., Wanner G., Wolf H. Assembly and extracellular release of chimeric HIV-1 Pr55gag retrovirus-like particles. Virology 1994, 200:162-175.
15. Tobin G.J., Li G.H., Fong S.E., Nagashima K., Gonda M.A. Chimeric HIV-1 virus-like particles containing gp120 epitopes as a result of a ribosomal frameshift elicit gag- and SU-specific murine cytotoxic T-lymphocyte activities. Virology 1997, 236:307-315.
16. Wagner R., Deml L., Schirmbeck R., Niedrig M., Reimann J., Wolf H. Construction, expression and immunogenicity of chimeric HIV-1 virus-like particles. Virology 1996, 220:128-140.
17. Deml L., Kratochwil G., Osterrieder N., Knuchel R., Wolf H., Wagner R. Increased incorporation of chimeric human immunodeficiency virus type 1 gp120 proteins into Pr55gag virus-like particles by an Epstein-Barr virus gp220/350-derived transmembrane domain. Virology 1997, 235:10-25.
18. Buonaguro L., Buonaguro F.M., Tornesello M.L., Mantas D., Beth-Giraldo E., Wagner R., et al. High efficient production of Pr55gag Virus-like Particles expressing multiple HIV-1 epitopes, including a gp120 protein derived from an Ugandan HIV-1 isolate of subtype A. Antivir Res 2001, 49:35-47.
19. Li Y., Luo L., Thomas D.Y., Kang C.Y. Control of expression, glycosylation, and secretion of HIV-1 gp120 by homologous and heterologous signal sequences. Virology 1994, 204:266-278.
20. Boublik Y., Di Bonito P., Jones I.M. Eukaryotic virus display: engineering the major surface glycoprotein of the Autographa californica nuclear polyhedrosis virus (AcNPV) for the presentation of foreign proteins on the virus surface. Biotechnology (N Y) 1995, 13:1079-1084.
21. Crooks E.T., Moore P.L., Franti M., Cayanan C.S., Zhu P., Jiang P., et al. A comparative immunogenicity study of HIV-1 virus-like particles bearing various forms of envelope proteins, particles bearing no envelope and soluble monomeric gp120. Virology 2007, 366(September (2)):245-262.
22. Wang B.Z., Liu W., Kang S.M., Alam M., Huang C., Ye L., et al. Incorporation of high levels of chimeric human immunodeficiency virus envelope glycoproteins into virus-like particles. J Virol 2007, 81(October (20)):10869-10878.
23. Santi L., Huang Z., Mason H. Virus-like particles production in green plants. Methods 2006, 40(September (1)):66-76.
24. Tsunetsugu-Yokota Y., Morikawa Y., Isogai M., Kawana-Tachikawa A., Odawara T., Nakamura T., et al. Yeast-derived human immunodeficiency virus type 1 p55gag Virus-Like Particles activate dendritic cells (DCs) and induce perforin expression in gag-specific CD8+ T cells by cross-presentation of DCs. J Virol 2003, 77:10250-10259.
25. Scotti N., Alagna F., Ferraiolo E., Formisano G., Sannino L., Buonaguro L., et al. High-level expression of the HIV-1 Pr55gag polyprotein in transgenic tobacco chloroplasts. Planta 2009, 229(April (5)):1109-1122.
26. Carbonell L.F., Klowden M.J., Miller L.K. Baculovirus-mediated expression of bacterial genes in dipteran and mammalian cells. J Virol 1985, 56(October (1)):153-160.
27. Maranga L., Cruz P.E., Aunins J.G., Carrondo M.J. Production of core and virus-like particles with baculovirus infected insect cells. Adv Biochem Eng Biotechnol 2002, 74:183-206.
28. Gheysen D., Jacobs E., de Foresta F., Thiriart C., Francotte M., Thines D., et al. Assembly and release of HIV-1 precursor Pr55gag virus-like particles from recombinant baculovirus-infected insect cells. Cell 1989, 59:103-112.
29. Royer M., Cerutti M., Gay B., Hong S.-S., Devauchelle G., Boulanger P. Functional domains of HIV-1 gag-polyprotein expressed in baculovirus-infected cells. Virology 1991, 184:417-422.
30. Tobin G.J., Nagashima K., Gonda M.A. Use of the particle-forming properties of the HIV gag precursor for packaging additional epitopes into pseudovirions produced in the baculovirus-insect cell expression system. Intervirology 1996, 39:40-48.
31. Buonaguro L., Del Gaudio E., Monaco M., Greco D., Corti P., Beth-Giraldo E., et al. Heteroduplex mobility assay and phylogenetic analysis of V3 region sequences of HIV 1 isolates from Gulu - Northern Uganda. J Virol 1995, 69:7971-7981.
32. Buonaguro L., Buonaguro F.M., Russo F., Tornesello M.L., Beth-Giraldo E., Wagner R., et al. A novel gp120 sequence from an HIV-1 isolate of the A clade identified in North Uganda. AIDS Res Hum Retroviruses 1998, 14:1287-1289.
33. Buonaguro L., Racioppi L., Tornesello M.L., Arra C., Visciano M.L., Biryahwaho B., et al. Induction of neutralizing antibodies and CTLs in Balb/c mice immunized with Virus-like Particles presenting a gp120 molecule from a HIV-1 isolate of clade A (HIV-VLPAs). Antivir Res 2002, 54:189-201.
34. Buonaguro L., Visciano M.L., Tornesello M.L., Tagliamonte M., Biryahwaho B., Buonaguro F.M. Induction of systemic and mucosal cross-clade neutralizing antibodies in BALB/c mice immunized with human immunodeficiency virus type 1 clade A virus-like particles administered by different routes of inoculation. J Virol 2005, 79:7059-7067.
35. Buonaguro L., Devito C., Tornesello M.L., Schroder U., Wahren B., Hinkula J., et al. DNA-VLP prime-boost intra-nasal immunization induces cellular and humoral anti-HIV-1 systemic and mucosal immunity with cross-clade neutralizing activity. Vaccine 2007, 25(January (32)):5968-5977.
36. Tagliamonte M., Visciano M.L., Tornesello M.L., De S.A., Buonaguro F.M., Buonaguro L. Constitutive expression of HIV-VLPs in stably transfected insect cell line for efficient delivery system. Vaccine 2010, 28(September (39)):6417-6424.
37. Harrison R.L., Jarvis D.L. Transforming lepidopteran insect cells for continuous recombinant protein expression. Methods Mol Biol 2007, 388:299-316.
38. Jarvis D.L., Fleming J.A., Kovacs G.R., Summers M.D., Guarino L.A. Use of early baculovirus promoters for continuous expression and efficient processing of foreign gene products in stably transformed lepidopteran cells. Biotechnology (New York) 1990, 8(October (10)):950-955.
39. Kato T., Murata T., Usui T., Park E.Y. Comparative analysis of GFP(UV)-beta1,3-N-acetylglucosaminyltransferase 2 production in two insect-cell-based expression systems. Protein Expres Purif 2004, 35(May (1)):54-61.
40. Tagliamonte M., Vidal N., Tornesello M.L., Peeters M., Buonaguro F.M., Buonaguro L. Genetic and phylogenetic characterization of structural genes from non-B HIV-1 subtypes in Italy. AIDS Res Hum Retroviruses 2006, 22:1045-1051.
41. Laemmli U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970, 227:680-685.
42. Dey A.K., David K.B., Klasse P.J., Moore J.P. Specific amino acids in the N-terminus of the gp41 ectodomain contribute to the stabilization of a soluble, cleaved gp140 envelope glycoprotein from human immunodeficiency virus type 1. Virology 2007, 360(March (1)):199-208.
43. Rovinski B., Haynes J.R., Cao S.X., James O., Sia C., Zolla-Pazner S., et al. Expression and characterization of genetically engineered human immunodeficiency virus-like particles containing modified envelope glycoproteins: implications for development of a cross- protective AIDS vaccine. J Virol 1992, 66:4003-4012.
44. Milne R.G. Electron microscopy of in vitro preparations. Diagnosis of plant virus diseases 1993, 215-251. CRC Press, Boca Raton, FL, USA. R.E.F. Matthews (Ed.).
45. Martelli G.P., Russo M. Use of thin sectioning for the visualization and identification of plant virus. Methods Virol 1984, 8:143-224.
46. Hallenberger S., Tucker S.P., Owens R.J., Bernstein H.B., Compans R.W. Secretion of a truncated form of the human immunodeficiency virus type 1 envelope glycoprotein. Virology 1993, 193(March (1)):510-514.
47. Earl P.L., Broder C.C., Long D., Lee S.A., Peterson J., Chakrabarti S., et al. Native oligomeric human immunodeficiency virus type 1 envelope glycoprotein elicits diverse monoclonal antibody reactivities. J Virol 1994, 68:3015-3026.
48. Binley J.M., Sanders R.W., Clas B., Schuelke N., Master A., Guo Y., et al. A recombinant human immunodeficiency virus type 1 envelope glycoprotein complex stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits is an antigenic mimic of the trimeric virion-associated structure. J Virol 2000, 74(January (2)):627-643.
49. Sanders R.W., Vesanen M., Schuelke N., Master A., Schiffner L., Kalyanaraman R., et al. Stabilization of the soluble, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1. J Virol 2002, 76(September (17)):8875-8889.
50. Ganser-Pornillos B.K., Yeager M., Sundquist W.I. The structural biology of HIV assembly. Curr Opin Struct Biol 2008, 8(April (2)):203-217.
51. Pornillos O., Ganser-Pornillos B.K., Kelly B.N., Hua Y., Whitby F.G., Stout C.D., et al. X-ray structures of the hexameric building block of the HIV capsid. Cell 2009, 137(June (7)):1282-1292.
52. Pornillos O., Ganser-Pornillos B.K., Banumathi S., Hua Y., Yeager M. Disulfide bond stabilization of the hexameric capsomer of human immunodeficiency virus. J Mol Biol 2010, 401(September (5)):985-995.
53. Ehrlich L.S., Agresta B.E., Carter C.A. Assembly of recombinant human immunodeficiency virus type 1 capsid protein in vitro. J Virol 1992, 66(August (8)):4874-4883.
54. Binley J.M., Wrin T., Korber B., Zwick M.B., Wang M., Chappey C., et al. Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies. J Virol 2004, 78:13232-13252.
55. Buchacher A., Predl R., Strutzenberger K., Steinfellner W., Trkola A., Purtscher M., et al. Generation of human monoclonal antibodies against HIV-1 proteins; electrofusion and Epstein-Barr virus transformation for peripheral blood lymphocyte immortalization. AIDS Res Hum Retroviruses 1994, 10(April (4)):359-369.
56. Burton D.R., Pyati J., Koduri R., Sharp S.J., Thornton G.B., Parren P.W., et al. Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science 1994, 266(November (5187)):1024-1027.
57. Burton D.R., Barbas C.F., Persson M.A., Koenig S., Chanock R.M., Lerner R.A. A large array of human monoclonal antibodies to type 1 human immunodeficiency virus from combinatorial libraries of asymptomatic seropositive individuals. Proc Natl Acad Sci U S A 1991, 88(November (22)):10134-10137.
58. Zhu P., Liu J., Bess J., Chertova E., Lifson J.D., Grise H., et al. Distribution and three-dimensional structure of AIDS virus envelope spikes. Nature 2006, 441(June (7095)):847-852.
59. Westenberg M., Wang H., IJkel W.F., Goldbach R.W., Vlak J.M., Zuidema D. Furin is involved in baculovirus envelope fusion protein activation. J Virol 2002, 76(January (1)):178-184.
60. Burton D.R., Desrosiers R.C., Doms R.W., Koff W.C., Kwong P.D., Moore J.P., et al. HIV vaccine design and the neutralizing antibody problem. Nat Immunol 2004, 5(March (3)):233-236.
61. Karlsson Hedestam G.B., Fouchier R.A., Phogat S., Burton D.R., Sodroski J., Wyatt R.T. The challenges of eliciting neutralizing antibodies to HIV-1 and to influenza virus. Nat Rev Microbiol 2008, 6(February (2)):143-155.
62. Stamatatos L., Morris L., Burton D.R., Mascola J.R. Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine?. Nat Med 2009, 15(August (8)):866-870.
63. Pyle L.E., Barton P., Fujiwara Y., Mitchell A., Fidge N. Secretion of biologically active human proapolipoprotein A-I in a baculovirus-insect cell system: protection from degradation by protease inhibitors. J Lipid Res 1995, 36(November (11)):2355-2361.
64. Yamada K., Nakajima Y., Natori S. Production of recombinant sarcotoxin IA in Bombyx mori cells. Biochem J 1990, 272(December (3)):633-636.
65. Jarvis D.L., Summers M.D. Glycosylation and secretion of human tissue plasminogen activator in recombinant baculovirus-infected insect cells. Mol Cell Biol 1989, 9(January (1)):214-223.